title: 177Lu-DOTATATE treatment in neuroendocrine tumours. A preliminary study.
abstract: Therapy with radiolabelled somatostatin analogue peptides is a promising new therapy to treat neuroendocrine tumours. The aim of this preliminary study is to present our experience with177Lu-DOTATATE therapy, and evaluate tolerability and short-term efficacy in patients with tumours expressing somatostatin receptors. A total of 7 patients with metastatic neuroendocrine tumours were treated, each with 4 doses of177Lu-DOTATATE. The treatment response was evaluated in the form of biochemical response (tumour markers), imaging methods (somatostatin receptor scintigraphy, computed tomography, and magnetic resonance), and functional and quality of life responses using the Karnofsky performance status scale. Treatment toxicity was also evaluated. The results obtained were as follows: Biochemical response: 60% of patients showed tumour marker levels returning to normal, while they decreased significantly in the remaining 40%. Imaging response: 85.7% had a partial response, while 14.3% showed stable disease. All (100%) patients showed a significant improvement in quality of life, with increased Karnofsky scale scores. No patient had acute or chronic toxicity, and subacute transient haematological toxicity was observed in 42.8% of patients. Despite being a preliminary study, it was found that treatment with177Lu-DOTATATE is a safe treatment with few side effects, and an objective response was achieved in most patients.
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España. Electronic address: hervas_isaben@gva.es.
authors.forename: I
authors.initials: I
authors.lastname: Hervás
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
authors.forename: P
authors.initials: P
authors.lastname: Bello
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
authors.forename: M
authors.initials: M
authors.lastname: Falgas
authors.affiliation: Servicio de Endocrinología, Hospital Universitario La Fe, Valencia, España.
authors.forename: M I
authors.initials: MI
authors.lastname: Del Olmo
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
authors.forename: I
authors.initials: I
authors.lastname: Torres
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
authors.forename: C
authors.initials: C
authors.lastname: Olivas
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
authors.forename: V
authors.initials: V
authors.lastname: Vera
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
authors.forename: P
authors.initials: P
authors.lastname: Oliván
authors.affiliation: Servicio de Medicina Nuclear, Hospital Universitario La Fe, Valencia, España.
authors.forename: A M
authors.initials: AM
authors.lastname: Yepes
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008187:Lutetium / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis; D018358:Neuroendocrine Tumors / Q000532:radiotherapy* / Q000556:secondary; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011788:Quality of Life; D011868:Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011877:Radionuclide Imaging / Q000379:methods; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000032:analysis; D014018:Tissue Distribution; D016896:Treatment Outcome; D051598:Whole Body Imaging / Q000379:methods; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; D008187:Lutetium; C447941:lutetium Lu 177 dotatate; C000615061:Lutetium-177; D015282:Octreotide
keywords: (177)Lu-DOTATATE; Neuroendocrine tumours; Radionuclide therapy; Terapia con radionúclidos; Tumores neuroendocrinos